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Renal denervation (RDN) is a new perspective method for the treatment of resistant
hypertension. Surgical sympathectomy has been considered as a possible treatment of
hypertension for many years—long before the discovery of antihypertensive drugs. The
selective percutaneous transcatheter application of radiofrequency energy in renal arteries to
eliminate sympathetic nerve fibers has been used in human medicine since 2009. The recent
boom of this method has been supported by published clinical studies showing efficacy of this
new treatment modality. Nevertheless, RDN is still an experimental method to be used only in
specialized research centers. In this review we will provide up-to-date information about the
use of RND as a novel method for the treatment of hypertension as well as discuss potential
perspectives of RND in the treatment of various medical conditions.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Prevalence of hypertension is very high in the Czech Republic
(47.8% of males and 36.6% of females aged 25–64 years) and itch Society of Cardiology.
petr@yahoo.com (P. Kala)is one of the most frequent cardiovascular diseases as well [1].
Arterial hypertension, as well as smoking, diabetes mellitus
and hyperlipidaemia, is an important risk factor for coronary
artery disease, cerebrovascular disease and peripheral arteryPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
.
.
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cardiovascular and cerebrovascular death.
Arterial hypertension is defined as repeated measurements
of blood pressure (BP) Z140/90mmHg at least at two clinical
visits [1,2]. Although there are many antihypertensive drugs
available and there is a clear evidence that treatment of
hypertension reduces the risk of death and complications,
only half of treated patients are well compensated (blood
pressure o140/90mmHg) [3].
Resistant hypertension is defined as the blood pressure
remaining above the target level despite the treatment with a
combination of 3 different, full-dose antihypertensive drugs
including diuretic. This definition presumes the patient be
adherent to treatment and thus resistant hypertension is not
synonymous to uncontrolled hypertension. Resistant hyperten-
sion does not include patients with BP over the target level due
to inadequate (under)treatment by their physician and also
patients with unrecognized secondary hypertension. On the
contrary, patients with well controlled BP with 4 and more
antihypertensive drugs meet the definition of resistant hyper-
tension [4]. In ALLHAT study, 8% of patients had 4 or more
antihypertensive agents and estimated overall prevalence of
resistant hypertension was 15% [5]. Many of these patients were
not ‘‘truly’’ resistant as the criteria for this condition were
poorly defined in this trial [2]. Small studies demonstrated the
prevalence of resistant hypertension be much more than 5%
but accurate estimate is not possible due to many bias [6,7].
Pikus et al. found 9.8% prevalence in the cohort of 620 patients
in a specialized center for hypertension. The definition of
resistant hypertension was sufficient but patients’ compliance
was unclear [8]. Alternative treatment strategies have been
studied for patients with resistant hypertension.RRA 
LRA
Fig. 1 – Aortography of descendent aorta and renal arteries;
RRA—right renal artery, LRA—left renal artery, pigtail
catheter (white arrow).2. Sympathetic nervous system (SNS)
Increased sympathetic activity plays an important role in
hypertensive patients. Muscle sympathetic nerve activity
(MSNA) was significantly higher in patients with severe essen-
tial hypertension than in normotensive controls and correlated
with mean arterial pressure [9,10]. Increased levels of catecho-
lamines were found in internal organs (heart, kidneys) of
hypertensive patients [11]. In a historical study by Peet et al.
that had been performed before the era of antihypertensive
drugs began, the blood pressure significantly lowered after
surgical sympathectomy. Major neurological symptoms includ-
ing headache and ophtalmological disturbances as well as
cardiac and renal status improved. Mortality of this procedure
was relatively high (more than 3%) and side adverse events
(orthostatic hypotension, bradycardia etc.) were also frequent
[12]. Kidneys are innervated with efferent and afferent adre-
nergic neurons. These neurons terminate in nephrons and
affect sodium reabsorption, renin secretion and renal blood
flow. Sympathetic stimulation causes expansion of blood
volume, vasoconstriction (vascular response to norepinephrine
and angiotensine II stimulation) and increase of arterial blood
pressure. The afferent neurons are linked to control centers for
neuromodulation in the midbrain (mesencephalon). Renal
afferent signaling is activated by renal ischemia and adenosin
release, both caused by intense vasoconstriction.Mechanoreceptors in renal pelvis are also involved. Increase
of afferent sympathetic traffic results in efferent sympathetic
response and vice versa and this potent kidney–brain sympa-
thetic loop may potentially become self-perpetuating [13].
Higher sympathetic activity persisted in patients with end-
stage renal failure who did not undergo bilateral nephrectomy
(interruption of the afferent sympathetic nerves). Having
removed the diseased kidneys, normalization of pathological
sympathetic overactivity was demonstrated [14]. Both afferent
and efferent sympathetic fibers are noradrenergic and are
situated in andventitia of renal arteries. Kidneys have an
important role on the overall sympathetic tone [15].3. Hypertension and renal denervation
All the knowledge about the pathophysiology of renal function
and its role in sympathorenal mechanism of etiology of
hypertension led to an idea of selective destruction of sympa-
thetic fibers running along the renal arteries. Preclinical studies
in juvenile swines demonstrated that a catheter based
approach was safe and markedly reduced the content of
norepinephrine in the treated kidney by more than 85%. No
significant vascular or renal injury was observed 6 months after
the procedure in these animal studies, justifying the initiation
of first-in-man evaluation [16]. The radiofrequency catheter
ablation (renal denervation—RND) in human was percuta-
neously performed for the first time in 2009 by Schlaich. In a
59-year old patient, he demonstrated a 42% reduction in
norepinephrine spillover, sustained blood pressure decrease,
normalization of muscle sympathetic nerve activity and reduc-
tion of left ventricle mass during 1-year follow-up [15].
The entire procedure requires a femoral artery access with
an insertion of a 6F guiding catheter. Heparin is admini-
strated to achieve activated clotting time (ACT) Z250 s. The
RND procedure is performed via lumen of a renal artery. Prior
aortography with the visualization of renal arteries is neces-
sary (Fig. 1). Patients with accessory renal arteries should not
be indicated for the ablation. After appropriate positioning of
a specially-designed ablation catheter (Symplicitys; Medtro-
nic) in a distal part of the renal artery, having achieved a
Fig. 4 – Left renal artery with ‘‘notches’’ (stars) after ablation.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 0 2 – e 2 0 8e204sufficient contact with the arterial wall, radiofrequency
energy is delivered 5–6 times in each artery for no longer
than 2min per application. We start distally and pull back
towards the ostium of the artery, making 5mm gaps between
two spots and rotating the catheter by 901 each time (Fig. 2).
The last application is performed in the upper part of the
renal artery right behind the ostium in order to destroy high
density sympathetic nerves that are present in this location.
Only mild energy (8W) is delivered during each application.
Temperature and impedance are automatically monitored by
the console (Fig. 3). After the procedure, one can see notches-
like marks on ablated renal arteries (Fig. 4).
One of rare adverse complications is the spasm of the renal
artery which is very resistant and can persist for hours.
Fortunately, in most of the cases, it remains clinically silent
(Fig. 5).
As well as in clinical trials and published papers that we are
now going to discuss, we use radiofrequency energy to ablate
nerve fibers that are circumferentially distributed along the
renal artery. The optimal energy modality for denervations is
unknown. First-in-man ultrasound energy denervation
results have just been announced. The advantage over the
RF technology lies in its ability to denervate uniformly and
circumferentially while simultaneously cooling the endothe-
lial wall to secure safe, consistent and fast procedure.
Seven patients who underwent denervation with this novel
ultrasound system (PARADISE) experienced substantialFig. 2 – Position of denervation catheter in renal artery
(reprinted with permission of Medtronic, Czech Republic).
Fig. 3 – RF generator.systolic blood pressure reduction by 31mmHg in 60 days
[17]. Whether ultrasound energy proves to be applicable in
the future will require further investigations.4. Clinical trials
The safety of the procedure and efficacy in blood pressure
lowering were the primary outcomes of the first trial (Sym-
plicity HTN-1) [18]. Secondary outcomes included renal nor-
adrenalin spillover and changes in renal function. The study
was carried out at 5 centers in Australia and Europe and
comprised patients treated from June 2007 to November 2008
and clinically followed for 1 year. The inclusion criteria were
office systolic blood pressure 160mmHg and higher despite
treatment with 3 or more antihypertensive drugs including
diuretic or intolerance to medication. Secondary hyperten-
sion was the major exclusion criterion and also patients with
renovascular disease were not enrolled. Out of 50 patients
only 45 were treated, 5 patients were excluded due to
anatomical criteria (accessory renal artery etc.). Repeated
renal angiogram was performed after 14–30 days and mag-
netic resonance angiogram at 6 months. At baseline, mean
blood pressure was 177/101mmHg, average number of anti-
hypertensive agents was 4.7, 43 patients were treated with
diuretics. Average amount of energy applications was 4.2 in
the right and 3.7 in the left artery. Analgetics and sedation
were administered during the procedure. Concerning com-
plications, there was one dissection of a renal artery caused
by the guiding catheter and was treated with stenting and
one femoral access site complication. Mean reduction of
blood pressure of 14/10mmHg at 1 month and further
continuous decrease up to 27/17mmHg at 12 months was
achieved (Fig. 6). Mean reduction of noradrenalin spillover
was 47%.
Thirteen patients did not respond to therapy—there was no
decrease in blood pressure. In 9 patients the antihypertensive
medication post procedure had to be reduced while in 4
patients increased.
Fig. 5 – Left—artery before ablation, right—spasm of side branch (white arrow), tip of Symplicity catheter (black arrow).
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Fig. 6 – Change of office blood pressure (modified from [18]).
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Fig. 7 – Change in office blood pressure (modified from [19]).
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with 24-month follow-up and published in 2011. 153 patients
were treated at 19 centers. Baseline BP was 176/98717/
15mmHg, average number of antihypertension agents was
5. Procedures were without any complications in 97% of
patients, 3 patients had groin pseudoaneurysm, 1 patient
had renal artery dissection. Office blood pressure postprocedure was reduced by 32/14mmHg at 24 months. The
reduction of blood pressure during the follow-up period is
shown in Fig. 7 [19].
The study was open-label and lasted for 4 years (from 2007
to 2010). Either 6 F (55pts) or 8 F (98pts) guiding catheters
were used. It was recommended that renal arteries be
minimally 4mmwide and 2cm long and without a significant
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 0 2 – e 2 0 8e206stenosis or previous renal stenting. Bradycardia was observed
during ablation in 10% of patients. Authors concluded that in
patients with resistant hypertension the catheter sympa-
thetic denervation resulted in substatial reduction of BP
during 2 years of follow-up without clinically significant
adverse events. But it is worthy of notice that only 18 patients
completed the 24-month follow-up [19].
Recently published The Symplicity HTN-2 trial was already
a randomized controlled study. 106 patients were allocated to
renal denervation therapy (n¼52) or pharmacological therapy
only (n¼54). The primary end-point was a change of seated
office-based systolic BP at 6 months. Inclusion criteria were
similar to those in the first trial. Baseline BP was 178/
96mmHg in the treated group and 178/97 in the control
group. At 6 months, patients in the treated group achieved
mean BP reduction by 32/21mmHg while there was no
change in the control group (þ1/0mmHg). The difference
between the groups was statistically significant (Po0.0001).
The reduction of systolic BP by 10mmHg or more was
observed in 84% of patients in the treated group vs. 35% in
the control group (Po0.0001). No serious procedure/device-
related complications occured. 3 patients in each group were
lost to follow-up. Mean ambulatory 24-hour BP was reduced
more in the denervation group (11/7mmHg vs. 3/1mmHg).
Seven patients developed bradycardia during the procedure
that was treated with atropine, 1 patient had groin pseudoa-
nerysm (Fig. 8) [20].
Outcomes in The Symplicity HTN trials are very encoura-
ging but there are several limitations to mention. Both trials
were unblinded so placebo effect was possible. Patients with
accessory renal arteries were not included in the trial and
investigations of possible secondary etiology of hypertension
were not sufficient. Reasons for nonresponding to the ther-
apy were not explained. Moreover, both baseline and follow-
up BP results were based only on office measurements (only
few patients had 24-hour BP monitoring) and white coat
syndrome might have played an important role. The occur-
ance of late renal artery stenosis was not investigated.
The Symplicity HTN-3 trial is a multi-centre, prospective,
single blind, randomized controlled study of safety and
efficacy of RND. This study is currently recruiting patients,
target number is over 500. Patients in the control group
undergo a sham procedure in order to partially reduce the
potential placebo effect, of course without the typical pain-20
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Fig. 8 – Symplicity HTN-2-primary endpothat is common in patients undergoing real denervations.
The primary endpoint is the change in office BP after 6
months, the secondary endpoint is the change of systolic
BP during the 24-hour ambulatory monitoring [21].5. RND and other diseases
Increased renal sympathetic activity is associated with com-
ponents of the metabolic syndrome [22]. There is a bidirec-
tional relationship between sympathetic overactivity and
insulin resistance and hyperinsulinemia—one can initiate
another [23]. Mahfoud evaluated the role of renal denervation
in glucose metabolism. 37 patients underwent renal denerva-
tion, 13 patients were in a control group. Fasting glucose was
reduced from 11873.4 to 10873.8mg/dL (P¼0.039), insulin
levels decreased from 20.873.0 to 9.372.5 mIU/mL (P¼0.006),
C-peptide levels from 5.370.6 to 3.070.9ng/mL (P¼0.002) and
insulin resistance from 6.070.9 to 2.470.8ng/mL (P¼0.001)
during 3-month follow-up. The substantial improvement in
insulin sensitivity and glucose metabolism in response to
RDN may be explained by reduced release of norepinephrin
on regional hemodynamics and direct cellular effect (increase
in norepinephrin leads to impaired ability of the cell to trans-
port glucose across its membrane). There were no significant
changes in the control group. Improvement was unrelated to
changes in pharmacological treatment (Fig. 9) [24].
Witkowski et al. [25] evaluated the effect of renal denervation
in a cohort of 10 patients with refractory hypertension and sleep
apnea syndrome. Denervation lowered blood pressure which
was accompanied by improvement of sleep apnea severity as
evaluated by apnea-hypopnea index at 6 months (median 16.3
vs. 4.5 events per hour; P¼0.059). Significant changes were also
observed in plasma glucose levels 2h after glucose administra-
tion (median 7.0 vs. 6.4mmol/L; P¼0.05) and in hemoglobin A1C
level (median 6.1% vs. 5.6%; Po0.05) at 6 months. Authors
concluded that denervation might be a useful option for patients
with glucose intolerance, comorbid hypertension and sleep
apnea syndrome. Better blood pressure control leading to a
reduction in fluid shifts to the neck in a lying position was
suggested as a possible explanation of the positive effect of renal
denervation on patients with sleep apnea syndrome [26].
Sympathetic nerve activity is increased in patients with
chronic heart failure and leads to higher morbidity and-8
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Fig. 9 – Changes of parametres associated with glucose metabolism from baseline to 3 months after renal denervation. All
changes in the denervation group and the differences between RND/control group at 3 months are statisticaly significant [24].
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 0 2 – e 2 0 8 e207mortality. In a study by Hasking et al. [27] patients with heart
failure and ejection fraction of 10–38% had mean plasma
norepinephrine levels significantly higher compared to sub-
jects without heart failure. Hasking also measured norepi-
nephrine activity in individual organs. Norepinephrine spillover
was increased mainly in heart and kidneys of the heart failure
patients (increased by 540%, resp. 206%) but no such finding
was confirmed in lungs. It has also been well documented in
large clinical trials that treatment with ACE inhibitors, beta-
blockers and angiotensin II blockers in chronic heart failure
patients lead to better outcomes concerning death, worsening
of heart failure and hospitalizations for decompensated heart
failure. Renal denervation reduces sympathetic activity and
activity of rennin–angiotensin–aldosteron system [28–33]. The
rationale for treatment of chronic heart failure patients with
renal denervation is clear and very promising. In heart failure
animals after surgical renal denervation the blood flow and
vascular resistance remained unchanged. Angiotensin II type 1
receptor expression is increased and type 2 decreased in heart
failure condition. After renal denervation performed in animals
with heart failure the abnormal expression of both receptors in
kidneys almost returned to normal values [34]. Brandt et al. [35]
compared 46 patients with left ventricle (LV) hypertrophy who
underwent renal denervation to 18 control subjects. Renal
sympathetic denervation reduced LV filling pressure, shortened
isovolumic relaxation time and increased LV ejection fraction.
Recently published first-in-men experience suggests that renal
denervation can be successfully used also in unstable chronic
heart failure patients with electrical storm [36].6. Conclusion
Over past 2 years we have learned to live with huge enthusiasm
and strong belief in renal sympathetic denervation. There is a
conceivable positive effect of RND not only on blood pressure
reduction in patients with resistant hypertension but RND may
also influence diseases associated with sympathetic hyperactiv-
ity like chronic heart failure, diabetes mellitus or sleep apnea
syndrome. Presently, many cardiologists consider implementa-
tion of this method into their clinical practice. But it is very
important to confirm promising results in large clinical trials
beforewe start using renal denervation as a routine intervention.Meanwhile renal denervation remains in hands of research
specialists as an experimental method for further investigations.
The Statement of the Czech Society of Cardiology as well as The
Position Paper from the European Society of Hypertension
provide practical recommendations, personnel and material
requirements for performing renal denervations [37,38].
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